NCT04214067 2026-05-13Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial CancerNational Cancer Institute (NCI)Phase 3 Active not recruiting164 enrolled